Biomarkers for therapies directed at angiogenesis

Current Colorectal Cancer Reports

Volumn 6, Issue 3, 2010, Pages 133-143

  Alsina, Maria ^a   Ruiz Echarri, Manuel ^a   Capdevila, Jaume ^a   Muñoz, Eva ^a   Tabernero, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Angiogenesis; Bevacizumab; Biomarkers; Everolimus; Pazopanib; Sorafenib; Sunitinib; Temsirolimus

Indexed keywords

ALPHA2A INTERFERON; AXITINIB; BEVACIZUMAB; CEDIRANIB; EVEROLIMUS; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; IRINOTECAN; K RAS PROTEIN; LACTATE DEHYDROGENASE; MOTESANIB; PACLITAXEL; PAZOPANIB; PLACENTAL GROWTH FACTOR; SCATTER FACTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BREAST CANCER; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; DRUG EFFICACY; ENDOTHELIUM CELL; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; PATIENT SELECTION; PROTEIN BLOOD LEVEL; REVIEW; SOLID TUMOR; SURVIVAL RATE;

EID: 79952738254     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-010-0057-y     Document Type: Review

References (53)

1. Sessa C, Guibal A, Del Conte G, Rüegg C: Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol 2008, 5:378-391. This is an excellent review that puts into perspective the development of angiogenesis biomarkers in the oncology setting.
2. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342. (Pubitemid 38702844)
3. Giantonio BJ, Catalano PJ, Meropol NJ, et al.: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOL-FOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25:1539-1544. (Pubitemid 46733080)
4. Sandler A, Gray R, Perry MC, et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550. (Pubitemid 44917502)
5. Reck M, von Pawel J, Zatloukal P, et al.: Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010 Feb 11 (Epub ahead of print).
6. Miller K, Wang M, Gralow J, et al.: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
7. Robert NJ, Dieras V, Glaspy J, et al.: RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2009, 27:1005.
8. Friedman HS, Prados MD, Wen PY, et al.: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-4740.
9. Escudier B, Pluzanska A, Koralewski P, et al.: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370:2103-2111. (Pubitemid 350296300)
10. Demetri GD, van Oosterom AT, Garrett CR, et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338. (Pubitemid 44528723)
11. Motzer RJ, Hutson TE, Tomczak P, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124. (Pubitemid 46089672)
12. Raymond E, Niccoli-Sire P, Bang Y, et al.: Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET) [abstract 127]. Presented at the 2010 Gastrointestinal Cancers Symposium, American Society of Clinical Oncology. Orlando, FL; January 22-24, 2010.
13. Escudier B, Eisen T, Stadler WM, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134. (Pubitemid 46089673)
14. Escudier B, Eisen T, Stadler WM, et al.: Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.
15. Llovet JM, Ricci S, Mazzaferro V, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
16. Hudes G, Carducci M, Tomczak P, et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271-2281. (Pubitemid 46849157)
17. Motzer RJ, Escudier B, Oudard S, et al.: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456.
18. Sternberg CN, Davis ID, Mardiak J, et al.: Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
19. Jubb AM, Hurwitz HI, Bai W, et al.: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006, 24:217-227. (Pubitemid 46622051)
20. Willett CG, Duda DG, di Tomaso E, et al.: Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009, 27:3020-3026. In this interesting study, the authors analyzed several potential angiogenic biomarkers with regard not only to the combination of chemotherapy and the antiangiogenic drug, but also to the effect of the combination with radiotherapy.
21. Hanrahan EO, Ryan AJ, Mann H, et al.: Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 2009, 15:3600-3609. The results of the biomarker analyses of this retrospective study are consistent with the previous idea that higher VEGF plasma levels are related to poorer prognosis. Unfortunately, these results have not been observed in similar trials.
22. Dowlati A, Gray R, Sandler AB, et al.: Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab - an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008, 14:1407-1412. (Pubitemid 351413922)
23. Ramalingam SS, Mack PC, Vokes EE, et al.: Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): a California Consortium phase II study. Proc Am Soc Clin Oncol 2008, 26:8078.
24. Burstein HJ, Chen YH, Parker LM, et al.: VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008, 14:7871-7877.
25. Jonasch E, Corn P, Pagliaro LC, et al.: Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 2010, 116:57-65.
26. Rini BI, Michaelson MD, Rosenberg JE, et al.: Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008, 26:3743-3748.
27. Rosen LS, Kurzrock R, Mulay M, et al.: Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007, 25:2369-2376. (Pubitemid 46999207)
28. Fruehauf JP, Lutzky J, McDermott DF, et al.: Axitinib (AG-013736) in patients with metastatic melanoma: a phase II study. Proc Am Soc Clin Oncol 2008, 26:9006.
29. Zeng ZS, Cohen AM, Guillem JG: Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 1999, 20:749-755. (Pubitemid 29191855)
30. Jonker DJ, Rosen LS, Sawyer M, et al.: A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings. Proc Am Soc Clin Oncol 2007, 25:3559.
31. Wang X, Saro J, Wei Z, et al.: Modelling TKI258 exposure and biomarker response in support of phase I dosing schedule finding. Proc Am Soc Clin Oncol 2008, 26:14691.
32. Nikolinakos PG, Altorki N, Yankelevitz D, et al.: Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 2010, 70:2171-2179. This study is an excellent example of how a biomarker may be useful in finding the best treatment schedule.
33. Hanrahan EO, Lin HY, Kim ES, et al.: Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010, 28:193-201.
34. Kopetz S, Hoff PM, Morris JS, et al.: Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010, 28:453-459. This well-designed phase 2 study evaluated the role of several potential biomarkers as prognostic factors and predictors of primary and secondary resistance to chemotherapy.
35. Tyagi P: Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. Clin Colorectal Cancer 2005, 5:24-26.
36. Kohne C, Bajetta E, Lin E, et al.: Final results of CONFIRM 2: a multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo. Proc Am Soc Clin Oncol 2007, 25:4033.
37. Bertolini F, Shaked Y, Mancuso P, Kerbel RS: The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006, 6:835-845. (Pubitemid 44629895)
38. Batchelor TT, Sorensen AG, di Tomaso E, et al.: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95. (Pubitemid 46075199)
39. Mancuso P, Burlini A, Pruneri G, et al.: Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001, 97:3658-3661.
40. Shaked Y, Emmenegger U, Man S, et al.: Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005, 106:3058-3061. (Pubitemid 41565900)
41. Norden-Zfoni A, Desai J, Manola J, et al.: Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007, 13:2643-2650. (Pubitemid 46788031)
42. Zhu AX, Sahani DV, Duda DG, et al.: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009, 27:3027-3035.
43. Schneider BP, Wang M, Radovich M, et al.: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 26:4672-4678. The evaluation of VEGF genotype as a predictive biomarker has emerged from the results of this study.
44. Lambrechts D, Delmar P, Buysschaert I, et al.: VEGFR-1 polymorphisms as potential predictors of clinical outcome in bevacizumab-treated patients with metastatic pancreatic cancer. Eur J Cancer 2009, 7:16LBA.
45. Zhang W, Dahlberg SE, Yang D, et al.: Genetic variants in angiogenesis pathway associated with clinical outcome in NSCLC patients (pts) treated with bevacizumab in combination with carboplatin and paclitaxel: subset pharmacogenetic analysis of ECOG 4599. Proc Am Soc Clin Oncol 2009, 27:8032.
46. Ince WL, Jubb AM, Holden SN, et al.: Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005, 97:981-989. (Pubitemid 41430564)
47. Hurwitz HI, Yi J, Ince W, et al.: The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009, 14:22-28.
48. Wilson PM, Yang D, Shi MM, et al.: Use of intratumoral mRNA expression of genes involved in angiogenesis and HIF1 pathway to predict outcome to VEGFR tyrosine kinase inhibitor (TKI) in patients enrolled in CONFIRM1 and CONFIRM2. Proc Am Soc Clin Oncol 2008, 26:4002.
49. Rini BI, Schiller JH, Fruehauf JP, et al.: Association of diastolic blood pressure (dBP) >90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). Proc Am Soc Clin Oncol 2008, 26:3543.
50. Liu G, Rugo HS, Wilding G, et al.: Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005, 23:5464-5473.
51. Drevs J, Siegert P, Medinger M, et al.: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007, 25:3045-3054. (Pubitemid 47218051)
52. Meijerink MR, van Cruijsen H, Hoekman K, et al.: The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol 2007, 17:1700-1713. (Pubitemid 46909659)
53. Chen W, Delaloye S, Silverman DHS, et al.: Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 2007, 25:4714-4721. (Pubitemid 350086472)